Understanding HoLEP - Advances in Prostate Treatment - Dr Jeevagan Murugesan

Published Date: 01 Mar 2023

Benign prostatic hyperplasia (BPH) is a condition in which the prostate gland enlarges, causing problems or obstruction in urination...

Read Full News

Latest News

This Test Could Predict Incontinence Risk After HoLEP

Men with a shorter membranous urethra appear more likely to experience urinary incontinence after laser enucleation for benign prostatic hyperplasia, a new study shows.

Smartphone App Helps Delay Ejaculation

The app improves sexual control and doubles ejaculation latency time in a randomized trial.

US FDA Approves Lantheus' New Prostate Cancer Imaging Formulation

The U.S. Food and Drug Administration on Friday approved a new formulation of Lantheus Holdings' prostate ⁠cancer imaging agent, aimed at improving scanning access through...

Will a Smart Toilet Turn the Home Into a Diagnostic Center?

Smart toilets show promise for passive monitoring of stool and urine to detect potential health issues, but challenges remain.

Bayer Sues Johnson & Johnson Over Claim That Prostate Cancer Drug Cuts Risk Of Death

Bayer sued Johnson & Johnson on Monday, accusing the drugmaker of falsely advertising that its rival multibillion-dollar drug cuts the ⁠risk of death from prostate...

Doc Murdered 8 Patients? RFK Jr. Will 'Cost Lives'; $412M in Penile Injection Case

Health news and commentary gathered by MedPage Today staff

Todays Updates

Why Encouragement May Not Improve Motivation in Depression

A meta-analysis identifies impaired effort-based decision making across psychiatric disorders, pointing to actionable targets for improving motivation and functional outcomes.

Assisted Dying Under Scrutiny From Medscape's Readers

Comments on a Medscape feature push past ideology to ask what evidence, oversight, and safeguards should be available for patients who choose assisted death.

Chemotherapy Boosts Survival for Older Patients With TNBC

Patients aged 70 years or older stand to benefit from adjuvant chemotherapy for triple-negative breast cancer, but the majority do not receive it.

Venetoclax Combo Shows Promise in Younger Patients With AML

Researchers conducted a systematic review and meta-analysis for studies of acute myeloid leukemia patients with a median age less than 70 treated with HMA plus venetoclax.

Radioligand Therapy Set to Transform Oncology Care

Nearly 400 trials and Belgium’s isotope hub signal rapid clinical diversification for radioligand therapy — but policy, funding, and system readiness must follow.

Todays Updates

Why Encouragement May Not Improve Motivation in Depression

A meta-analysis identifies impaired effort-based decision making across psychiatric disorders, pointing to actionable targets for improving motivation and functional outcomes.

Assisted Dying Under Scrutiny From Medscape's Readers

Comments on a Medscape feature push past ideology to ask what evidence, oversight, and safeguards should be available for patients who choose assisted death.

Chemotherapy Boosts Survival for Older Patients With TNBC

Patients aged 70 years or older stand to benefit from adjuvant chemotherapy for triple-negative breast cancer, but the majority do not receive it.

Venetoclax Combo Shows Promise in Younger Patients With AML

Researchers conducted a systematic review and meta-analysis for studies of acute myeloid leukemia patients with a median age less than 70 treated with HMA plus venetoclax.

Radioligand Therapy Set to Transform Oncology Care

Nearly 400 trials and Belgium’s isotope hub signal rapid clinical diversification for radioligand therapy — but policy, funding, and system readiness must follow.

Latest News

Men with a shorter membranous urethra appear more likely to experience urinary incontinence after laser enucleation for benign prostatic hyperplasia, a new study shows.

The app improves sexual control and doubles ejaculation latency time in a randomized trial.

The U.S. Food and Drug Administration on Friday approved a new formulation of Lantheus Holdings' prostate ⁠cancer imaging agent, aimed at improving scanning access through...

Smart toilets show promise for passive monitoring of stool and urine to detect potential health issues, but challenges remain.

Bayer sued Johnson & Johnson on Monday, accusing the drugmaker of falsely advertising that its rival multibillion-dollar drug cuts the ⁠risk of death from prostate...

Health news and commentary gathered by MedPage Today staff

News All Time

King Charles III's Operation; COVID-19 Timeline Under Question; FDA Approvals Reach Record High.

The staff of MedPage Today has compiled health news and commentary from around the web.

Noninvasive Treatment Effective in Bladder Cancer That Is Not Muscle-Invasive.

An investigational intrusive solution produced a 79% complete response rate.

For Prostate Cancer at Intermediate Risk, SBRT Is Not Less Effective Than Conventional RT.

Similar results are obtained from treatment lasting one to two weeks as compared to therapy lasting up to seven and a half weeks.

Even in those with HIV, a single dose of antibiotics was able to cure early syphilis.

In a randomized trial, one dosage showed no worse results than a triple-dose regimen.

Should Patients With Advanced Prostate Cancer Get Off the Active Surveillance Train?

Clearly defined rules are needed.

The new first-line standard for advanced bladder cancer was produced by a landmark trial.

When compared to chemotherapy, enfortumab vedotin-pembrolizumab doubles OS and PFS.

An RCT Supports HIF-2a Inhibition in Advanced RCC.

Belzutifan outperforms everolimus in the event of immunotherapy-TKI failure.

AR-Pathway Inhibitor Switch for mCRPC is Superseded by Radionuclide Therapy.

With 177Lu-PSMA-617, the time to radiographic progression was doubled.

Cabazitaxel Lower-Dose Schedule Is Viable for Elderly Patients With mCRPC.

Neutropenia of grade three or above, with a twelve-fold reduction in neutropenic consequences.

Removing Cancer Survivors From Oncologic Treatment.

A new approach to care is required.

In severe cases of renal cell carcinoma, tyrosine kinase inhibitor activity is present.

Reactions to the "special medication" zanzalintinib in patients exposed and not exposed to cabozantinib.

Finding New Routes to Improve Renal Cell Carcinoma Outcomes.

It is necessary to intervene at several stages of the cancer immunity cycle in order to build on recent successes.

CAR T-Cell Therapy for Renal Cell Carcinoma: "We're Not There Yet".

Possibility of standard of care following current therapies, but significant barriers still need to be overcome.

Dietary inflammation is associated with the development of urologic cancers.

In health research, the relationship between dietary habits and cancer risks is still a major focus. The has been the subject of a recent meta-analysis.

In infants, laparoscopic robotic pyeloplasty is safe and has a success rate comparable to open surgery.

The results of minimally invasive pyeloplasty (MIP) for the primary cause, ureteropelvic junction obstruction (UPJO), were examined in a recent study.

Medical Bulletin November 30, 2023.

The top medical stories of the day are as follows: ADHD increases the risk of car crashes in older adults. ADHD is a neurodevelopmental disorder that is chronic and has symptoms.

Recommended News For You

High levels of traumatic stress found in caregivers of adult cancer patients

Journal Club: A well-accepted and safe method for soft tissue sarcoma biopsy.

Additional Proof of the Different Cognitive Effects of ARSIs for Prostate Cancer.

Alcohol Causes Cancer. We Should Be Drinking Less.

A new blood test greatly increases the ability to detect cancer.

Adding Targeted Agent to Perioperative Therapy for RCC May Improve Disease Control

PFS in Multiple Myeloma Is Improved by Daratumumab Added to Standard Therapy.

Recommended Articles For You

AI in Cancer Care: Transforming Research & Treatment with Deep Learning Technologies 

New Hope for Rectal Cancer Patients: Breakthrough Drug Shows Promising Results 

Unlocking the Mysteries of ICD 10 Code Normocytic Anemia 

The Importance of Early Detection in Angiosarcoma: A Story of Survival  

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

ALK-positive lung cancer trial results show unprecedented progression-free survival.

2.

MET Inhibitor Increases Osimertinib Activity in EGFR+ Advanced NSCLC

3.

Research finds low uptake of supportive care at the end-of-life for patients with advanced cancer

4.

Children with cancer tumors lacking DNA repair may benefit from olaparib combined with ceralasertib.

5.

Resection for Early Liver Cancer Tied to Improved Survival.

1.

The Potential of Amifostine in Cancer Treatment: A Revolutionary Breakthrough

2.

Survival Rate Dynamics in Hematologic and Solid Malignancies

3.

Multimodal Data Fusion with Deep Neural Networks - Revolutionizing Oncology with Precision Cancer Diagnosis 2025

4.

The Capmist DM: A Revolutionary Way to Combat Dry Mouth

5.

Biologic Therapies for Cutaneous Immune-Related Adverse Events in the Era of Immune Checkpoint Inhibitors

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion

2.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part II

3.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV

4.

Treatment Paradigm for Patients with R/R Adult B-cell ALL- Expert Discussions

5.

Newer Immunotherapies for Myeloma- A Comprehensive Overview


Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot